诺格白介素α-因奇西普(Nogapendekin alfa inbakicept-pmln) - 药物靶点：IL-15 x IL-2Rβγ_在研适应症：淋巴细胞减少，非肌层浸润性膀胱肿瘤，转移性非小细胞肺癌_专利_临床

概要

基本信息

药物类型

Fc融合蛋白

别名

IL-15N72D:IL-15RαSu/Fc fusion protein complex、Inbakicept、Nogapendekin alfa inbakicept

+ [6]

靶点

IL-15 x IL-2Rβγ

作用方式

激动剂、刺激剂

作用机制

IL-15激动剂(白细胞介素-15激动剂)、IL-2Rβγ激动剂(白细胞介素-2受体βγ亚基复合物激动剂)、免疫刺激剂

治疗领域

肿瘤泌尿生殖系统疾病呼吸系统疾病+ [9]

在研适应症

淋巴细胞减少非肌层浸润性膀胱肿瘤转移性非小细胞肺癌+ [26]

非在研适应症

急性早幼粒细胞白血病晚期恶性实体瘤晚期三阴性乳腺癌+ [18]

原研机构

Altor BioScience Corp.

在研机构

ImmunityBio, Inc.

Altor BioScience Corp.Serum Life Science Europe GmbH

+ [1]

非在研机构-

权益机构

Altor BioScience Corp.

深圳市北科生物科技有限公司

最高研发阶段批准上市

首次获批日期

美国 (2024-04-22),

非肌层浸润性膀胱肿瘤

最高研发阶段(中国)临床2期

特殊审评突破性疗法 (美国)、快速通道 (美国)

登录后查看时间轴

结构/序列

Sequence Code 14770950

关联

84

项与诺格白介素α-因奇西普相关的临床试验

NCT07085338

/ Recruiting临床2期IIT

A Phase II Study With a Safety Run-In of the Addition of N-803, a Novel IL-15 Super-Agonist, to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

The study participant is being asked to take part in this research study because the participant has been diagnosed with neuroblastoma that did not fully respond to previous treatment (refractory), or it has returned after treatment (relapsed).
Primary Aims
* To evaluate if the administration of N-803 in combination with irinotecan, temozolomide, hu14-18K322A, and GM-CSF in patients with relapsed/refractory neuroblastoma is feasible and tolerable
* To determine if the response rate of N-803 with irinotecan, temozolomide, hu14.18K322A and GM-CSF in patients with relapsed/refractory neuroblastoma is superior to the combination of irinotecan, temozolomide, hu14.18K322A, and GM-CSF
Secondary Aims
* To describe the toxicity profile of N-803 administered with irinotecan, temozolomide, hu14.18K322A and GM-CSF
* To evaluate and compare the progression free survival (PFS) and overall survival (OS) of and between patients receiving irinotecan, temozolomide, hu14.18K322A and GM-CSF with and without N-803

开始日期2025-12-01

申办/合作机构

St. Jude Children's Research Hospital, Inc.

NCT07217496

/ Not yet recruiting临床1期IIT

Phase Ib Trial Combining N-803 and Pembrolizumab With Shorter Duration of Enfortumab Vedotin in Treatment-Naïve Patients With Metastatic Urothelial Carcinoma

This phase Ib trial will investigate the effect of N-803 in combination with pembrolizumab and enfortumab vedotin in treating participants with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic).

开始日期2025-11-30

申办/合作机构

The University of California, San Francisco

[+1]

NCT06829823

/ Not yet recruiting临床2期

Phase 2 Clinical Trial of Ablation Therapy With Intravesical N-803 In Combination With BCG or Gemcitabine in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

This is an open-label, phase 2, randomized study of intravesical N-803 plus BCG (experimental arm A) and intravesical N-803 plus gemcitabine (experimental arm B) in participants who have intermediate-risk Ta/T1 papillary disease. The primary objective of this study is to evaluate the efficacy of these experimental therapies without the need for surgical intervention by CR rate at month 3 or month 6 (for re-inducted participants).

开始日期2025-11-01

申办/合作机构

ImmunityBio, Inc.

100 项与诺格白介素α-因奇西普相关的临床结果

登录后查看更多信息

100 项与诺格白介素α-因奇西普相关的转化医学

登录后查看更多信息

100 项与诺格白介素α-因奇西普相关的专利（医药）

登录后查看更多信息

99

项与诺格白介素α-因奇西普相关的文献（医药）

2025-11-01·CURRENT OPINION IN UROLOGY

Traditional and next-generation bacillus Calmette-Guérin based treatment strategies for bacillus Calmette-Guérin unresponsive non-muscle-invasive bladder cancer in the era of emerging therapies

Review

作者: Burgos Revilla, Francisco Javier ; Subiela, José Daniel ; Guerrero-Ramos, Felix ; Pichler, Renate ; Artiles Medina, Alberto

Purpose of review:

Bacillus Calmette–Guérin (BCG) remains the standard of care for high-risk non-muscle-invasive bladder cancer (NMIBC), yet up to 40–50% of patients experience treatment failure, leaving limited alternatives to avoid radical cystectomy. This narrative review critically examines both traditional and emerging BCG-based strategies – including repeat induction and modern combination regimens – for patients with BCG-unresponsive NMIBC.

Recent findings:

BCG monotherapy after BCG failure has shown limited effectiveness, with recent studies reporting 12-month disease-free survival (DFS) rates of 60–70%. Nonetheless, BCG continues to serve as an immunotherapeutic backbone in combination strategies. Chemo-immunotherapy regimens, particularly those using gemcitabine or mitomycin C, have achieved 1-year DFS rates of up to 80%. Combinations with cytokines and immunocytokines – such as interferon-α or nogapendekin alfa inbakicept-pmln (NAI) – have demonstrated DFS rates of 45–61%, and NAI has recently received FDA approval. Immune checkpoint inhibitors (e.g., pembrolizumab, durvalumab, atezolizumab) in combination with BCG have shown DFS rates ranging from 42 to 73% at 12 months. However, many studies are limited by small sample sizes and heterogeneous designs.

Summary:

Despite its limited efficacy as monotherapy in unresponsive cases, BCG retains therapeutic relevance as part of combination strategies that enhance its immunologic activity. Emerging data suggest that these BCG-based regimens offer a promising, bladder-sparing alternative for patients who are ineligible for or decline radical cystectomy. Ongoing and future trials will be essential to define optimal combinations and identify which patients are most likely to benefit, thereby enabling appropriate patient selection.

2025-10-15·CLINICAL CANCER RESEARCH

FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ

Article

作者: Pierce, William F. ; Dellibovi-Ragheb, Teegan A. ; Heiss, Brian L. ; Tang, Shenghui ; Chiu, Haw-Jyh ; Rahman, Nam Atiqur ; Koh, Eun Hee ; Joeng, Hee-Koung ; Suzman, Daniel L. ; Kluetz, Paul G. ; Pazdur, Richard ; Wang, Min ; Chang, Elaine ; Amiri-Kordestani, Laleh ; Leighton, John K. ; Ricks, Tiffany K. ; Lee, Christal ; Wang, Lingshan ; Fiero, Mallorie H. ; Hamed, Salaheldin S.

Abstract:

On April 22, 2024, the U.S. FDA granted regular approval to nogapendekin alfa inbakicept-pmln (N-803) with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Substantial evidence of effectiveness for this application was obtained from cohort A of the single-arm, multicenter QUILT-3.032 trial. Patients received N-803 400 μg administered intravesically with TICE BCG once a week for 6 weeks as induction therapy, a second induction course if complete response (CR) was not achieved at month 3, and maintenance N-803 with BCG weekly for 3 weeks at months 4, 7, 10, 13, and 19 (for a total of 15 maintenance doses). The major efficacy outcome measures were CR at any time [as defined by negative results for cystoscopy [with transurethral resection of bladder tumor (TURBT)/biopsies as applicable] per local investigator assessment and urine cytology] and duration of response. The CR rate in the 77-patient efficacy population, per FDA review, was 62% [95% confidence interval (CI), 51%–73%]. Of the 48 patients with a CR, 28 (58%; 95% CI, 26%–55%) and 19 (40%; 95% CI, 16%–36%) maintained a response for ≥12 months and ≥24 months, respectively. The most common adverse reactions were increased creatinine, dysuria, hematuria, urinary frequency, urinary urgency, and urinary tract infection. This article summarizes the data and FDA thought process supporting the approval of N-803 with BCG.

2025-08-19·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic CD8⁺ T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound.

Article

作者: Viox, Elise G ; Deleage, Claire ; Samer, Sadia ; Kuri-Cervantes, Leticia ; Betts, Michael R ; Paiardini, Mirko ; Safrit, Jeffrey T ; Davenport, Miles P ; Pampena, M Betina ; Regan, James ; Docken, Steffen ; Bar, Katharine J ; Wu, Vincent H ; Keele, Brandon F ; Nguyen, Kevin

A primary obstacle for HIV elimination is the long-term viral reservoir in lymphoid tissues (LT) that can cause rebound viremia if therapy is stopped. Cytotoxic CD8⁺ T cells are critical for control of HIV and Simian immunodeficiency virus (SIV) viremia; however, CD8⁺ T cells that migrate to LT are primarily noncytotoxic, calling into question whether these cells could reduce the viral reservoir on antiretroviral therapy (ART) or control viral replication when therapy is halted. To determine whether CD8⁺ T cells can inhibit viral replication when retained in LT, we inhibited lymphocyte egress from LTs in ART-treated SIV-infected rhesus macaques (RMs) during analytic treatment interruption (ATI) using the S1PR modulator FTY720 alone or in combination with anti-PD1 antibody (αPD1) and the IL-15 receptor superagonist N-803 to increase cytolytic function. FTY720 retained migrating CD4⁺ and CD8⁺ T cells in LT, whereas cytotoxic CD8⁺ T cells remained in the vasculature. After ATI and viral rebound, activated SIV-specific CD8⁺ T cells increased in frequency in LT of FTY720-treated RMs but failed to become cytotoxic or control plasma viremia compared to controls, even when combined with αPD1 and N-803. These findings indicate that LT-localized CD8⁺ T cells alone may be insufficient to delay or prevent plasma viral rebound during ATI.

236

项与诺格白介素α-因奇西普相关的新闻（医药）

2025-09-18

·香港证券交易所

海外監管公告 - 關於藥物納入擬突破性治療品種公示名單的公告

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司（於中華人民共和國註冊成立的股份有限公司）（股份代號：1276）海外監管公告本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。承董事會命江蘇恒瑞醫藥股份有限公司董事長孫飄揚先生中國上海 2025年9月18日於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。证券简称：恒瑞医药证券代码：600276 江苏恒瑞医药股份有限公司关于药物纳入拟突破性治疗品种公示名单的公告本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。近日,江苏恒瑞医药股份有限公司（以下简称“公司”）子公司上海恒瑞医药有限公司的注射用SHR-1501被国家药品监督管理局药品审评中心（以下简称“药审中心”）纳入拟突破性治疗品种公示名单，公示期7日。现将相关情况公告如下：一、药物的基本情况药物名称：注射用SHR-1501 受理号：CXSL2101496 药物类型：治疗用生物制品注册分类：1类申请日期：2025年7月23日拟定适应症（或功能主治）：注射用SHR-1501联合卡介苗（BCG）用于BCG无应答的非肌层浸润性原位癌（CIS）患者。理由及依据：经审核，本申请符合《药品注册管理办法》和《国家药监局关于发布＜突破性治疗药物审评工作程序（试行）＞等三个文件的公告》（2020年第82号）有关要求，同意纳入突破性治疗药物程序。二、药物的其他相关情况 SHR-1501为公司自主研发并具有知识产权的白细胞介素-15（IL-15）融合蛋白，可以刺激体内T细胞、B细胞和NK细胞增殖，发挥调动机体免疫系统清除体内异物（如肿瘤）的作用，其与BCG联用可明显增强膀胱内的免疫反应，达到协同抗肿瘤的效果。与IL-2相比，IL-15不会刺激调节性T细胞增殖和诱导T细胞凋亡。目前国外同类产品Nogapendekin Alfa Inbakicept（商品名：Anktiva）已于美国获批上市销售，国内未有相同靶点产品获批上市。截至目前，注射用SHR-1501相关项目累计研发投入约10,218万元。三、风险提示根据《国家药监局关于发布＜突破性治疗药物审评工作程序（试行）＞等三个文件的公告》（2020年第82号），药审中心对纳入突破性治疗药物程序的药物优先配置资源进行沟通交流，加强指导并促进药物研发。药品研发容易受到技术、审批、政策等多方面因素的影响，审评政策及未来药品市场竞争形势等存在诸多不确定性风险，上述产品存在突破性治疗药物程序公示期被提出异议的风险。敬请广大投资者谨慎决策，注意防范投资风险。公司将按国家有关规定积极推进上述研发项目，并及时对项目后续进展情况履行信息披露义务。特此公告。江苏恒瑞医药股份有限公司董事会

突破性疗法ASH会议申请上市

2025-09-10

·FiercePharma

J&J's 'practice-changing' bladder cancer therapy Inlexzo lands FDA nod

With an 82% complete response rate seen in trials, Johnson & Johnson has touted high market hopes for the med. The FDA has signed off on Johnson & Johnson’s highly anticipated bladder cancer drug Inlexzo, marking an advance in the ability to care for patients who otherwise face bladder removal and limited treatment options.Inlexzo, previously called TAR-200, can now treat patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.The drug-releasing system combo allows for extended release of the chemotherapy gemcitabine directly to patients' bladders through an intravesical system that can be placed in minutes in an outpatient setting, with no general anesthesia needed, J&J said in a Sept. 9 release.Before the approval, the typical treatment route for NMIBC patients who don’t respond to standard-of-care BCG therapy was a radical cystectomy to remove the entire bladder. It's a life-altering and risky procedure that's not appropriate for many patients. J&J’s offering, meanwhile, provides a “potentially practice-changing” treatment, the company said.“We are proud of the science that has brought us to this historic moment,” John Reed, M.D., Ph.D., head of R&D at J&J Innovative Medicine, said in a statement. “As the only major healthcare company that hosts both pharmaceuticals and medical devices, we leveraged the speed and scale of Johnson & Johnson to accelerate innovation and deliver this important therapy to patients.”J&J picked up the asset from Taris Biomedical in 2019 with hopes to “give patients with bladder cancer a renewed sense of hope and belief,” Jennifer Taubert, J&J's head of Innovative Medicine, commented. “In an area that has seen little progress for more than 40 years, Inlexzo delivers a first-of-its-kind breakthrough innovation with a bright future ahead.” In a phase 2b study, 82% of Inlexzo-treated patients experienced a complete response without the need for reinduction, with 51% maintaining the response for at least one year. The complete response rate is the highest recorded among currently available therapies, Mark Wildgust, Ph.D., vice president of oncology global medical affairs for J&J Innovative Medicine, said in an interview with Fierce Pharma earlier this year.With its high complete response rate and its convenience factor, J&J believes Inlexzo will set itself apart from other bladder cancer offerings such as Merck’s Keytruda, Ferring Pharmaceuticals’ gene therapy Adstiladrin and ImmunityBio’s immunotherapy Anktiva, which is used alongside the BCG vaccine. The company has high hopes for the drug’s market potential.“In all the research that we have done, I have absolutely no reason to believe that they will use anything else but us once they fail BCG,” the president of J&J’s solid tumor business, Biljana Naumovic, told Fierce Pharma in April. She acknowledged, however, that the drug won’t reach that level of market dominance right away. J&J has already set up a patient support program and a Care Navigator offering educational resources at no cost to patients. Inlexzo is being further studied across patients with MIBC and those with NMIBC in four ongoing clinical trials.

临床结果临床2期免疫疗法疫苗上市批准

2025-08-28

·药明康德

100%疾病控制率！潜在重磅疗法组合积极试验结果公布；诺和诺德达成5.5亿美元RNA疗法合作

100%疾病控制率！潜在重磅疗法组合积极试验结果公布 ImmunityBio近日公布一项探索性研究的最新结果。该研究评估其免疫增强方案用于治疗5例复发性胶质母细胞瘤（GBM）患者的疗效与安全性。该方案包含IL-15激动剂Anktiva（nogapendekin alfa inbakicept，旨在增强自然杀伤细胞活性）、NK细胞疗法（PD-L1 t-haNK）以及Optune Gio肿瘤电场治疗装置。分析显示，在接受治疗的5名患者中，3名患者获得缓解，其中2名接近完全缓解，另2名至今维持疾病稳定，患者的整体疾病控制率（DCR）达100%。新闻稿指出，对于复发性GBM二线患者而言，这一无需化疗方案的积极试验结果极具意义。基于这一初步发现，ImmunityBio计划启动一项随机对照临床试验，专门针对在标准治疗后仍出现疾病复发的二线GBM患者。 Anktiva是一款IL-15超级激动剂。该疗法在2019年获FDA授予突破性疗法认定，用于与卡介苗（BCG）联合治疗此前对BCG应答不佳的非肌层浸润性原位膀胱癌患者。2024年4月，美国FDA批准Anktiva与BCG联合使用，用于治疗对BCG无应答且伴有原位癌的非肌层浸润性膀胱癌成年患者，这些患者伴或不伴有乳头状肿瘤。值得一提的是，行业媒体Evaluate曾将这款疗法列为2024年有望获批的10款潜在重磅疗法之一。诺和诺德达成5.5亿美元RNA疗法合作 Replicate Bioscience今日宣布与诺和诺德（Novo Nordisk）达成一项为期多年的研究合作。此次合作将结合诺和诺德在治疗和药物开发方面的深厚经验，以及Replicate创新的自我复制RNA（srRNA）平台，共同开发用于治疗肥胖、2型糖尿病及其他心脏代谢疾病的新型候选疗法。根据协议，双方将在特定心脏代谢疾病靶点上展开合作，诺和诺德将获得Replicate srRNA平台的全球独家许可，用于开发和商业化相关项目。Replicate将获得研究经费，并有资格从诺和诺德处获得高达5.5亿美元的资金支持，包括预付款和潜在里程碑付款等款项。 Replicate拥有完善的srRNA专有技术，可根据需求定制蛋白表达特征。相比其他RNA技术，其平台在体内表现出更高水平的蛋白表达、更持久的效果以及更灵活的调控能力。Replicate正通过其创新的srRNA技术克服传统RNA疗法的不足，在生物活性、免疫反应强度及治疗指数方面展现出提升潜力。目前，公司研发的临床阶段狂犬病疫苗RBI-4000已在1期试验中显示出在低于其他RNA疫苗剂量下实现保护性免疫水平的成果。参考资料： [1] Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes. Retrieved August 28, 2025 from https://www.prnewswire.com/news-releases/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes-302540245.html [2] Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device. Retrieved August 28, 2025 from https://www.businesswire.com/news/home/20250826147574/en/Initial-Data-Shows-100-Disease-Control-in-5-Out-of-5-Patients-With-Recurrent-Glioblastoma-With-Two-Patients-in-Near-Complete-Response-Treated-With-ImmunityBios-ANKTIVA-NK-Cell-Therapy-Plus-Optune-Gio-Device 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床1期突破性疗法临床2期临床结果

100 项与诺格白介素α-因奇西普相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12888	-	-	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
淋巴细胞减少	美国	ImmunityBio, Inc.	2025-06-02
非肌层浸润性膀胱肿瘤	美国	Altor BioScience Corp.	2024-04-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性非小细胞肺癌	临床3期	美国	ImmunityBio, Inc.	2025-10-01
膀胱癌	临床3期	美国	ImmunityBio, Inc.	2017-06-02
新冠肺炎后遗症	临床2期	美国	ImmunityBio, Inc.	2025-09-04
前列腺腺癌	临床2期	-	ImmunityBio, Inc.	2025-05-15
铂耐药性卵巢癌	临床2期	美国	ImmunityBio, Inc.	2024-11-06
复发性铂耐药性卵巢癌	临床2期	美国	ImmunityBio, Inc.	2024-11-06
多形性胶质母细胞瘤	临床2期	美国	ImmunityBio, Inc.	2024-08-07
胶质母细胞瘤，IDH野生型	临床2期	美国	ImmunityBio, Inc.	2024-08-07
头颈癌转移	临床2期	美国	ImmunityBio, Inc.	2024-02-16
复发性头颈癌	临床2期	美国	ImmunityBio, Inc.	2024-02-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NEWS 人工标引	N/A	复发性胶质母细胞瘤	5	Anktiva	鬱膚鬱壓鬱齋遞鬱簾網(觸網繭憲蓋淵顧廠醖餘) = 願窪蓋蓋壓鬱鏇築醖窪憲簾憲鑰鬱醖夢蓋鑰蓋 (簾廠遞壓遞齋範憲積觸 )	积极	2025-08-29
NCT04390399 (QUILT-88, ASCO2025)	临床2期	转移性胰腺癌 ALC \| CA19-9	84	N-803 and PD-L1 t-haNK chemo-immunotherapy	憲製繭糧糧網遞選願遞(窪糧選憲積選遞積襯願) = Grade 3 or higher TEAEs occurred in 95% of patients and were largely chemotherapy-associated 蓋鏇襯艱構齋餘淵顧鑰 (網鑰顧壓餘獵願積築鹹 )	积极	2025-05-30
				Low-dose SBRT and low-dose chemotherapy
NCT03022825 (QUILT-3.032, Company_Website \| Literature) 人工标引	临床2/3期	非肌层浸润性膀胱肿瘤	180	ANKTIVA®ANKTIVA® plus BCG (CIS with or without Papillary)	餘顧膚餘醖範選鹹繭選(構憲衊積顧顧憲壓簾構) = 積觸醖夢築衊鏇獵餘積鏇獵餘廠鹽願齋繭遞壓 (網膚築繭鬱膚衊願淵糧 ) 更多	积极	2025-04-28
				ANKTIVA® Plus BCG (Papillary without CIS)	鑰艱襯艱艱鹹製繭壓壓(憲鹽窪憲鏇鏇網醖夢製) = 顧築艱壓憲顧鑰獵願繭廠繭簾鬱積鑰範築繭鑰 (觸衊顧窪鑰願鏇襯顧糧 ) 更多
NCT03381586 (CTgov)	临床1期	-	20	ALT-803 (Group A)	範鏇憲選壓積艱鬱淵齋(憲觸襯鬱鹹憲鑰獵淵選) = 願鬱衊積獵構襯窪簾獵廠鑰壓淵艱鑰鬱製壓憲 (製積觸鑰製衊淵鬱膚製, 0.813) 更多	-	2025-03-24
				ALT-803 (Group B)	範鏇憲選壓積艱鬱淵齋(憲觸襯鬱鹹憲鑰獵淵選) = 簾壓鹽鑰鬱獵積繭餘鬱廠鑰壓淵艱鑰鬱製壓憲 (製積觸鑰製衊淵鬱膚製, 0.095) 更多
NCT03563157 (CTgov)	临床1/2期	转移性结直肠癌	2	SBRT+Aldoxorubicin Hydrochloride+GI-6301+GI-4000+ETBX-061+Cetuximab+ETBX-051+ETBX-011+5-fluorouracil+ALT-803+ETBX-021+Nab-paclitaxel+Cyclophosphamide+Avelumab+haNK+Leucovorin+GI-6207+Regorafenib+oxaliplatin+Capecitabine (NANT Colorectal Cancer (CRC) Vaccine)	膚範選構廠繭餘廠鹹願 = 醖製窪醖築鹹鏇繭鹽壓簾獵餘餘憲網願齋鹽壓 (鹽衊艱膚壓鹹餘顧餘範, 願鑰蓋獵餘醖襯積觸構 ~ 窪糧範鏇製廠繭憲糧廠) 更多	-	2024-12-11
				Regorafenib (Regorafenib)	鑰構膚醖鏇遞壓網遞鑰(遞廠願窪膚齋壓蓋窪鹹) = 衊積醖膚襯築淵顧鑰糧鑰窪選蓋鏇觸獵網醖壓 (壓夢艱齋構艱夢餘鑰製, 襯鏇廠廠鏇築鹹築鑰簾 ~ 簾願顧艱衊積鹽願觸選) 更多
NCT02099539 (CTgov)	临床1期	复发性多发性骨髓瘤 \| 难治性多发性骨髓瘤	19	N-803 (Cohort 1: N-803 - IV 1 ug/kg)	鹹憲構艱鹹積選鏇蓋糧 = 襯網餘鏇繭鹽觸簾鬱顧蓋網獵獵蓋鹽顧壓艱網 (顧襯鬱遞願簾鹽鹽製鹽, 壓範鑰憲繭壓獵遞繭淵 ~ 齋選獵遞範夢壓範獵積) 更多	-	2024-09-26
				N-803 (Cohort 2: N-803 - IV 3 ug/kg)	鹹憲構艱鹹積選鏇蓋糧 = 窪遞鏇艱構構鹽積蓋膚蓋網獵獵蓋鹽顧壓艱網 (顧襯鬱遞願簾鹽鹽製鹽, 齋簾齋獵範鑰膚衊餘醖 ~ 積餘艱糧窪糧鹽艱醖衊) 更多
NCT03493945 (QuEST1, ESMO2024)	临床1/2期	去势抵抗性前列腺癌 dMMR \| pMMR	25	BNVax + BA + Anktiva	獵築憲壓淵網觸壓鏇選(範窪簾艱願觸壓醖壓鹽) = 構獵選願齋鹽醖醖鏇簾範網製窪艱製淵淵觸簾 (鬱簾獵網鏇鑰網衊醖膚, 39.9 ~ 83.9) 更多	积极	2024-09-15
NCT03228667 (QUILT 3.055, WCLC2024) 人工标引	临床2期	非小细胞肺癌二线 \| 末线 \| 三线 PDL1+	86	Anktiva 15mcg/knivolumabvolupembrolizumab	淵蓋餘蓋膚膚窪壓觸鹽(淵廠淵鑰簾繭選艱網觸) = injection site reaction 78 (91%), fatigue 46 (53%), chills 36 (42%). 憲繭廠簾夢獵獵窪鏇鏇 (獵壓製夢糧鹽艱夢鏇築 )	积极	2024-09-08
				Anktiva + CPI (nivolumab or pembrolizumab)pembrolizumab) (failure of CPI + 3rd line)
NCT04385849 (CTgov)	临床1期	新型冠状病毒感染	1	N-803 (Experimental Arm)	網襯窪鹽網範淵鬱襯築 = 憲壓醖簾艱願窪鏇膚積衊餘廠觸齋廠鏇艱廠襯 (顧窪獵餘醖網膚襯獵艱, 願窪鹽鏇願餘齋鏇選積 ~ 獵蓋築遞襯廠襯鑰觸鏇) 更多	-	2024-09-05
				Saline (Placebo Arm)	網襯窪鹽網範淵鬱襯築 = 積淵壓齋餘繭糧網襯廠衊餘廠觸齋廠鏇艱廠襯 (顧窪獵餘醖網膚襯獵艱, 網鑰糧壓獵衊鑰製糧獵 ~ 衊鹽艱醖夢繭艱膚艱製) 更多
NCT03853317 (QUILT-3.063, CTgov)	临床2期	转移性Merkel细胞癌 \| 梅克尔细胞癌	9	N-803+Avelumab+haNK™	構願淵遞遞願糧廠膚積 = 範膚壓簾簾鑰憲築襯淵鏇簾製顧鹹餘餘遞範鹹 (鏇觸窪構獵築選壓醖膚, 簾構醖願鹹積糧簾積襯 ~ 餘積遞鏇獵憲膚糧醖鬱) 更多	-	2024-08-09